John C. Gutheil
Directeur Général chez Sciquus, Inc.
Profil
John C.
Gutheil is currently the President & Chief Executive Officer at Sciquus, Inc. He was previously the Chief Executive Officer at Proacta, Inc. from 2006 to 2011.
He also held positions at Vical, Inc., Sidney Kimmel Cancer Center, Favrille, Inc., the University of Maryland, and Aphelion Capital LLC.
Dr. Gutheil received his undergraduate degree from the University of California San Diego in 1979 and his doctorate from The Medical College of Wisconsin, Inc.
Postes actifs de John C. Gutheil
| Sociétés | Poste | Début |
|---|---|---|
| Sciquus, Inc. | Directeur Général | 01/01/2014 |
Anciens postes connus de John C. Gutheil
| Sociétés | Poste | Fin |
|---|---|---|
Aphelion Capital LLC
 Aphelion Capital LLC Investment ManagersFinance Aphelion Capital LLC (Aphelion Capital) is a venture capital firm founded in 2005 by Ned Scheetz and Rodney Altman. The firm is headquartered in Mill Valley, California. | Corporate Officer/Principal | 30/06/2009 |
| University of Maryland | Corporate Officer/Principal | - |
Sidney Kimmel Cancer Center
 Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Directeur Technique/Scientifique/R&D | - |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Directeur Général | - |
Formation de John C. Gutheil
| University of California San Diego | Undergraduate Degree |
| The Medical College of Wisconsin, Inc. | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
| Favrille, Inc. | Health Technology |
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
Aphelion Capital LLC
Aphelion Capital LLC Investment ManagersFinance Aphelion Capital LLC (Aphelion Capital) is a venture capital firm founded in 2005 by Ned Scheetz and Rodney Altman. The firm is headquartered in Mill Valley, California. | Finance |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Sidney Kimmel Cancer Center
Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Health Services |
| Sciquus, Inc. |
